BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20878643)

  • 1. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study.
    Huizinga MM; Roumie CL; Greevy RA; Liu X; Murff HJ; Hung AM; Grijalva CG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1108-12. PubMed ID: 20878643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year.
    Roumie CL; Liu X; Choma NN; Greevy RA; Hung AM; Grijalva CG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):515-23. PubMed ID: 22431419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
    Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort.
    Roumie CL; Huizinga MM; Liu X; Greevy RA; Grijalva CG; Murff HJ; Hung AM; Griffin MR
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):36-44. PubMed ID: 21182152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
    BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
    Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA
    J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
    Duckworth W; Marcelli M; Padden M; Kellick K; Duhancik T; Wilhardt M; Colgan K; Romie A
    J Manag Care Pharm; 2003; 9(3):256-62. PubMed ID: 14613469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic treatment patterns in a medicare advantage population in the United States.
    Slabaugh SL; Xu Y; Stacy JN; Baltz JC; Meah YA; Lian J; Moretz DC; Bouchard JR
    Drugs Aging; 2015 Feb; 32(2):169-78. PubMed ID: 25573537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
    JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.
    Barnett AH; Dreyer M; Lange P; Serdarevic-Pehar M
    Diabetes Care; 2006 Jun; 29(6):1282-7. PubMed ID: 16732009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes.
    Gatwood JD; Chisholm-Burns M; Davis R; Thomas F; Potukuchi P; Hung A; Kovesdy CP
    J Manag Care Spec Pharm; 2018 Apr; 24(4):379-389. PubMed ID: 29578849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.